Company Description
Idenix Pharmaceuticals is not suffering from any identity crisis -- it is clear in its focus on identifying treatments for life-threatening viruses....
Key Idenix Pharmaceuticals Financials
| Company Type | Public - NASDAQ (GM): IDIX Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $68.0 |
| 2005 Employees | 218 |
More Idenix Pharmaceuticals Financials (11 pages)
Latest Idenix Pharmaceuticals Jobs jobs by Indeed
Competition
Competitive Landscape for Biotechnology Sector
Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. The profitability of individual companies depends on the...
Read more about Idenix Pharmaceuticals's competition across multiple industries
Top Idenix Pharmaceuticals Competitors
Sponsored Links
The Business DirectoryTrading Toolbox
Idenix Pharmaceuticals Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman, President, and CEO | Jean-Pierre Sommadossi | Network | E-mail |
| SVP Human Resources | Paul J. Fanning | Network | E-mail |
| Senior Manager Corporate Communications | Teresa (Teri) Dahlman | Network | E-mail |
More Idenix Pharmaceuticals Executives
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Current Idenix Pharmaceuticals News
- Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections [U.S. Patents] (17 Jun 2008 12:28:00 EDT)
- Idenix Pharmaceuticals Inc (IDIX) Corporate Event Announcement Notice [Wall Street Horizon] (13 Jun 2008 20:52:00 EDT)
- BioWorld Today June 13, 2008 [BioWorld Today] (13 Jun 2008 00:01:00 EDT)
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.